Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 22Thoracic 9Head & Neck 6Gynecologic 6Genitourinary 6Breast 5Sarcoma 3Dermatologic 3Plasma cell 1Myeloid 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1

Interventions

Trastuzumab 2Quality of Life 2Fluorodeoxyglucose F18 2tislelizumab 1tipifarnib 1surufatinib 1regorafenib 1milademetan 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1entinostat 1copper dotatate CU-64 1Surveys and Questionnaires 1Ritonavir 1Radiotherapy 1Poly(ADP-ribose) Polymerase Inhibitors 1Patient Reported Outcome Measures 1PM 01183 1Oxaliplatin 1N-Ac-CHAVC-NH2 1Molecular Diagnostic Techniques 1Melphalan 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Gemcitabine × Endocrine × Clear all
NCT00178698 2011-03-03

FR-WB-TT/che

The University of Texas Health Science Center, Houston

Phase 2 Unknown
36 enrolled
EndocrineGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡